Richard Finn
MD
Professor
👥Biography 个人简介
Richard Finn at UCLA has made major contributions to two cancer types: leading the IMbrave150 trial establishing atezolizumab plus bevacizumab as the new standard first-line therapy for advanced HCC, dramatically improving survival compared to sorafenib; and contributing to the PALOMA-2 trial establishing palbociclib as the first CDK4/6 inhibitor in breast cancer. These practice-changing contributions span two major cancer types.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Richard Finn 的研究动态
Follow Richard Finn's research updates
留下邮箱，当我们发布与 Richard Finn（UCLA David Geffen School of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment